HOLLISTON, Mass., Dec. 6, 2016 /PRNewswire/ -- Biostage, Inc.
(Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology
company developing bioengineered organ implants to treat cancers
and other life-threatening conditions of the esophagus, bronchus
and trachea, today announced that Jim McGorry, CEO of Biostage,
will participate presentation and panel discussion at the 2016
World Stem Cell Summit and RegMed Capital Conference on
Wednesday, December 7th at
2:00 PM ET, being held at the
Palm Beach County Convention
Center, West Palm Beach,
Florida.
Mr. McGorry will provide an overview of the Company and outline
Biostage's expected upcoming near-term corporate, clinical and
regulatory milestones that will enable the Company's transition to
a clinical-stage company in 2017.
As part of his presentation, Mr. McGorry will discuss the
Company's lead product candidate, the Cellspan™ Esophageal Implant,
which recently received Orphan Drug Designation from the U.S. Food
and Drug Administration (FDA). The Cellspan Esophageal Implant is
designed to restore the structure and function of the esophagus
subsequent to esophageal damage due to cancer, injury or congenital
abnormalities.
About Regenerative Medicine Foundation
The World Stem
Cell Summit is a project of the nonprofit Regenerative Medicine
Foundation. Since 2003, Regenerative Medicine Foundation and its
predecessor Genetics Policy Institute have built the strongest,
most comprehensive and trusted global network of Regenerative
Medicine stakeholders, uniting the world's leading researchers,
medical centers, universities, labs, businesses, funders,
policymakers, experts in law, regulation and ethics, medical
philanthropies and patient organizations. Our mission is to
accelerate regenerative medicine to improve health and deliver
cures. We are committed to the ethical advancement of innovative
medicine powered by regenerative, restorative, and curative
technologies. Learn more at www.regmedfoundation.org.
About 2016 WSCS
The World Stem Cell Summit, is the
original, translation-focused global meeting of stakeholders, now
celebrating its 12th year. The 2016 WSCS is co-sponsored by the The
Mayo Clinic Center for Regenerative Medicine and is organized by
the Center for the Advancement of Science in Space (CASIS), the
sole manager of the International Space Station U.S. National
Laboratory; Centre For Commercialization Of Regenerative Medicine
(Canada); Diabetes Research
Institute Foundation; Kyoto University
Institute for Integrated Cell Material Science; Mayo Clinic;
NOVA Southeastern University Cell
Therapy Institute; The Cure Alliance; University of Miami Miller School of Medicine ISCI
(Interdisciplinary Stem Cell Institute); and Wake Forest School of
Medicine Institute for Regenerative Medicine. Learn more at
www.worldstemcellsummit.com.
About Biostage
Biostage is a biotechnology company
developing bioengineered organ implants based on the company's new
Cellframe™ technology which combines a proprietary biocompatible
scaffold with a patient's own stem cells to create Cellspan™ organ
implants. Cellspan implants are being developed to treat
life-threatening conditions of the esophagus, bronchus or trachea
with the hope of dramatically improving the treatment paradigm for
patients. Based on its preclinical data, Biostage has selected
life-threatening conditions of the esophagus as the initial
clinical application of its technology.
Cellspan implants are currently being advanced and tested in
collaborative preclinical studies. Preclinical, large-animal safety
studies, conducted in compliance with the FDA Good Laboratory
Practice (GLP) regulations, for the Company's Cellspan Esophageal
Implant product candidate are ongoing, in support of Biostage's
goal of filing an Investigational New Drug (IND) application with
the U.S. FDA in the third quarter of 2017. The IND will seek
approval to initiate clinical trials for its esophageal implant
product candidate in humans.
For more information, please visit www.biostage.com and connect
with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in
this press release are "forward-looking" and are made pursuant to
the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These "forward-looking" statements in this
press release include, but are not limited to, statements relating
to the development expectations and regulatory approval of any of
our products, including those utilizing our Cellframe technology,
by the U.S. Food and Drug Administration, the European Medicines
Agency or otherwise, which expectations or approvals may not be
achieved or obtained on a timely basis or at all; or success with
respect to any collaborations, clinical trials and other
development and commercialization efforts of our products,
including those utilizing our Cellframe technology, which
such success may not be achieved or obtained on a timely basis or
at all. These statements involve risks and uncertainties that may
cause results to differ materially from the statements set forth in
this press release, including, among other things, our ability to
obtain and maintain regulatory approval for our products; plus
other factors described under the heading "Item 1A. Risk Factors"
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 or described in our
other public filings. Our results may also be affected by factors
of which we are not currently aware. The forward-looking statements
in this press release speak only as of the date of this press
release. Biostage expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any
changes in the events, conditions or circumstances on which any
such statement is based.
Investor Relations
Contacts:
|
|
Tom
McNaughton
|
Jenene
Thomas
|
Chief Financial
Officer
|
Jenene Thomas
Communications LLC
|
774-233-7321
|
(908)
938-1475
|
tmcnaughton@biostage.com
|
jtc@jenenethomascommunications.com
|
|
|
Media
Contacts:
|
|
David Schull or
Maggie Beller
|
|
Russo Partners
LLC
|
|
212-845-4271 or
646-942-5631
|
|
Email:
Maggie.beller@russopartnersllc.com
|
|
Logo - http://photos.prnewswire.com/prnh/20160330/349802LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biostage-to-participate-at-the-2016-world-stem-cell-summit-and-regmed-capital-conference-300373301.html
SOURCE Biostage, Inc.